STING1 and cancer: Various immunostimulatory adjuvants, including agonists of PRRs (e.g. TLRs) or of their adapters (e.g. STING), have been developed to enhance the anti-cancer immunity induced by ICBs [239] and to overcome the resistance to systemic ICB therapies.